Table 2 Comparison of participant clinical characteristics and baseline ctDNA positivity

From: Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

 

Baseline ctDNA detection

 
 

All Patients (N = 114)

Not Detected (N = 26)

Detected (N = 88)

P-value

Receptor status, n (%)

   

0.151

 ER+

40 (35.1%)

12 (30.0%)

28 (70.0%)

 

 HER2+

45 (39.5%)

11 (24.4%)

34 (75.6%)

 

 TNBC

29 (25.4%)

3 (10.3%)

26 (89.7%)

 

Clinical T stage, n (%)

   

0.602

 T1/T2

74 (64.9%)

18 (24.3%)

56 (75.7%)

 

 T3/T4

40 (35.1%)

8 (20.0%)

32 (80.0%)

 

Clinical nodal status, n (%)

   

0.312

 N0

43 (37.7%)

12 (27.9%)

31 (72.1%)

 

 N1

71 (62.3%)

14 (19.7%)

57 (80.3%)

 

Clinical anatomic stage, n (%)

   

0.742

 I

6 (5.3%)

2 (33.3%)

4 (66.6%)

 

 II

77 (67.5%)

18 (23.4%)

59 (76.6%)

 

 III

31 (27.2%)

6 (19.4%)

25 (80.6%)

 

Grade (Diagnostic biopsy), n (%)

   

0.04982

 2

32 (28.1%)

12 (37.5%)

20 (62.5%)

 

 2 to 3

22 (19.3%)

5 (22.7%)

17 (77.3%)

 

 3

60 (52.6%)

9 (15.0%)

51 (85.0%)

 
  1. 1Fisher Exact p-value; 2Chi-Square p-value.
Back to article page